** RBC Capital Markets raises Biogen's BIIB.O price target to $213 from $205
** New PT implies a 68.6% upside to the stock's last close
** Brokerage says Biogen is approaching a catalyst-rich period with late-stage trial results expected from 2026 to 2028 for key drugs in rare kidney diseases, lupus, and Alzheimer's
** RBC believes there isn't one huge drug that will determine the company's fate, but rather several promising candidates, which spreads out the risk
** If all the drugs in the company's development pipeline succeed, the stock could rise by as much as 40%, brokerage says
** As of last close, BIIB stock down 17.4% YTD
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.